Face Transplantation Clinical Trial

Sponsor
The Cleveland Clinic (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT01269164
Collaborator
United States Department of Defense (U.S. Fed)
2
1
1
161
0

Study Details

Study Description

Brief Summary

The purpose of this study is to apply human facial allograft transplant to the subjects with severe facial deformities or disfigurements in order to provide adequate coverage, aesthetic appearance and functional outcome.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgical Procedure Composite Facial Transplant
N/A

Detailed Description

The human scalp and face define two important body units, both functionally and aesthetically. Traumatic deformities of the head and neck region resulting from burn injuries, gun shot wounds, or ablative tumor surgeries may involve the defect of the skin, subcutaneous tissue, muscle or the combination of all these elements. In most cases, the ideal reconstruction is very difficult to achieve. Sometimes, a major part of face along with the ear or the nose may be involved. The extensive scalp loss due to burn or avulsion injury is another deforming and psychologically debilitating condition presenting as a major reconstructive challenge. An ideal reconstructive procedure should replace the missing tissues and restore the motor and sensory function. Traditional reconstructive procedures of facial deformities involve skin grafting, local flap applications, tissue expansion, and prefabrication as well as free tissue transfers. The primary goal during facial reconstruction is restoration of the function and aesthetic appearance. To obtain satisfactory results, missing parts should be replaced only by tissues of the same color and texture. The purpose of this study is to apply human facial allograft transplant to the subjects with severe facial deformities or disfigurements in order to provide adequate coverage, aesthetic appearance and functional outcome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Protocol for Composite Facial Allograft Transplant
Study Start Date :
Jul 1, 2010
Actual Primary Completion Date :
Aug 1, 2020
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Face Transplantation

Surgical Procedure Composite Facial Transplant

Procedure: Surgical Procedure Composite Facial Transplant
Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
Other Names:
  • Face Transplant
  • Outcome Measures

    Primary Outcome Measures

    1. Evaluate the success of the face transplant [Patients will be carefully screened and monitored post-operatively for signs of rejection or flap failure for 5 years.]

      Demonstrate stable engraftment and restoration of facial skin/bone coverage and sensory-motor function in recipients of composite tissue allografts of vascularized skin, bone, and soft tissue augments(nose, ear, lips, eyelids, etc)under standard immunopression protocol.

    Secondary Outcome Measures

    1. Evaluate tolerogenic properties of the immunosuppression protocol [Patients will be carefully screened and monitored post-operatively for signs of rejection or flap failure for 5 years.]

      Characterize tolerogenic properties of our immunosuppression protocol, by monitoring of donor specific chimerism and presence of T regulatory cells in the face allograft transplant recipients.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subject must be willing to sign the informed consent and agree to all follow up procedures, including the realistic understanding of the impact of face allotransplantation on their lifestyle

    • Subjects will be evaluated by plastic surgeon to assess indications for facial allotransplantations based on severity and complexity of facial deformity

    • Subjects ages 18-60.

    • Subject must be willing to undergo a psychiatric and social services pre-transplantation evaluation

    • Subject must be willing to undergo major face surgery

    • Subject must be a candidate for general anesthesia

    • Subjects must be willing to comply with post transplant physical therapy.

    • Subject must be willing and able to receive potent drugs to induce and maintain immunosuppression and follow the infection prophylaxis protocol

    • Subject must be willing to receive standard vaccinations such as influenza, pneumococcus, and hepatitis B.

    • Subjects must be free of malignant tumors for 5 or more years with the exception of certain skin cancer.

    Exclusion Criteria:
    • Subject that shows history of persistent non-compliance

    • Findings of the psychiatric evaluation that may indicate non-compliance or mental instability

    • Presence of an active infection including Human Immunodeficiency Virus, mycobacteria, hepatitis B, and hepatitis C

    • Presence of an occult infection for example, dental abscess, UTI, tuberculosis, or history of systemic/occult infection within 3 months of surgery

    • Any current Chemical Dependency including alcohol

    • Subjects at high risk for the recurrence of malignancy with the exception of certain skin cancers

    • Any diagnosis that the qualifying plastic surgeon feels would put the subject at high risk for the surgical procedure of face transplantation

    • Subjects who do not have adequate donor site tissue available for coverage in the event of face transplant failure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • The Cleveland Clinic
    • United States Department of Defense

    Investigators

    • Principal Investigator: Frank Papay, MD, The Cleveland Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Frank Papay, MD, Institute Chair, Dermatology and Plastic Surgery Institute, The Cleveland Clinic
    ClinicalTrials.gov Identifier:
    NCT01269164
    Other Study ID Numbers:
    • IRB6914
    First Posted:
    Jan 4, 2011
    Last Update Posted:
    Jul 7, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Frank Papay, MD, Institute Chair, Dermatology and Plastic Surgery Institute, The Cleveland Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 7, 2022